PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study.

Abstract There are no treatment modalities, which were proven to prevent the deposition of amyloid, proteinuria, and loss of renal function due to amyloidosis. Anti-tumor necrosis factor agents (anti-TNFs) were shown to decrease the production of serum amyloid A protein.We aimed to evaluate the long-term efficacy and safety of anti-TNFs in secondary (AA) amyloidosis patients treated in a single center.Thirty-seven patients with AA amyloidosis were started an anti-TNF for AA amyloidosis between March 2001 and June 2008 and followed until May 2016 unless deceased. They were surveyed for the endpoints of death, development of end-stage renal disease (ESRD), switch to another agent due to worsening of amyloidosis and adverse events.Among the 37 patients, 12 (32%) had died, 9 (24%) had ESRD, and 8 (22%) had started another group of biologic due to worsening of amyloidosis indicated by an increase in proteinuria, 5 (14%) patients are still doing well with anti-TNFs, and 3 (8%) are off treatment at the end of a median follow-up of 10 (interquartile range [IQR]: 5.5-10.5) years since the start of anti-TNFs and 10 (IQR: 8-13) years since the diagnosis of AA amyloidosis. Most common serious adverse events were sepsis and thrombotic events observed in 8 and 4 patients, respectively.Treatment with anti-TNFs may be associated with a higher survival rate compared with historic cohorts of AA amyloidosis, especially when started early with a lower serum creatinine level at baseline. Caution is needed regarding serious adverse events, especially infections.
PMID
Related Publications

AA amyloidosis treated with tocilizumab: case series and updated literature review.

Turkish experience in rheumatoid arthritis patients with clinical apparent amyloid deposition.

AA amyloidosis complicating the hereditary periodic fever syndromes.

A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients.

Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28834898
OWN - NLM
STAT- In-Process
DA  - 20170823
LR  - 20170823
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 34
DP  - 2017 Aug
TI  - Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis
      factor inhibitor therapy: A STROBE-compliant observational study.
PG  - e7859
LID - 10.1097/MD.0000000000007859 [doi]
AB  - There are no treatment modalities, which were proven to prevent the deposition of
      amyloid, proteinuria, and loss of renal function due to amyloidosis. Anti-tumor
      necrosis factor agents (anti-TNFs) were shown to decrease the production of serum
      amyloid A protein.We aimed to evaluate the long-term efficacy and safety of
      anti-TNFs in secondary (AA) amyloidosis patients treated in a single
      center.Thirty-seven patients with AA amyloidosis were started an anti-TNF for AA 
      amyloidosis between March 2001 and June 2008 and followed until May 2016 unless
      deceased. They were surveyed for the endpoints of death, development of end-stage
      renal disease (ESRD), switch to another agent due to worsening of amyloidosis and
      adverse events.Among the 37 patients, 12 (32%) had died, 9 (24%) had ESRD, and 8 
      (22%) had started another group of biologic due to worsening of amyloidosis
      indicated by an increase in proteinuria, 5 (14%) patients are still doing well
      with anti-TNFs, and 3 (8%) are off treatment at the end of a median follow-up of 
      10 (interquartile range [IQR]: 5.5-10.5) years since the start of anti-TNFs and
      10 (IQR: 8-13) years since the diagnosis of AA amyloidosis. Most common serious
      adverse events were sepsis and thrombotic events observed in 8 and 4 patients,
      respectively.Treatment with anti-TNFs may be associated with a higher survival
      rate compared with historic cohorts of AA amyloidosis, especially when started
      early with a lower serum creatinine level at baseline. Caution is needed
      regarding serious adverse events, especially infections.
FAU - Esatoglu, Sinem Nihal
AU  - Esatoglu SN
AD  - aDivision of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical
      School, Istanbul University bDepartment of Internal Medicine, Cerrahpasa Medical 
      School, Istanbul University, Istanbul, Turkey.
FAU - Hatemi, Gulen
AU  - Hatemi G
FAU - Ugurlu, Serdal
AU  - Ugurlu S
FAU - Gokturk, Aycan
AU  - Gokturk A
FAU - Tascilar, Koray
AU  - Tascilar K
FAU - Ozdogan, Huri
AU  - Ozdogan H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
EDAT- 2017/08/24 06:00
MHDA- 2017/08/24 06:00
CRDT- 2017/08/24 06:00
AID - 10.1097/MD.0000000000007859 [doi]
AID - 00005792-201708250-00035 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Aug;96(34):e7859. doi: 10.1097/MD.0000000000007859.